Balyasny Asset Management
LFCR icon

Balyasny Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Balyasny Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,699
Closed -$101K – 3348
2025
Q3 		$101K Buy
13,699
+3,190
+30% +$24.1K ﹤0.01% 2789
2025
Q2 		$85.3K Buy
+10,509
New +$70.8K ﹤0.01% 2696
2024
Q2 		– Sell
-37,367
Closed -$198K – 2874
2024
Q1 		$198K Sell
37,367
-36,813
-50% -$263K ﹤0.01% 2410
2023
Q4 		$459K Buy
+74,180
New +$515K ﹤0.01% 1986
2023
Q3 		– Sell
-13,316
Closed -$129K – 2521
2023
Q2 		$129K Sell
13,316
-4,054
-23% -$24.8K ﹤0.01% 2105
2023
Q1 		$65.6K Buy
+17,370
New +$96.8K ﹤0.01% 2358
2016
Q2 		– Sell
-10,270
Closed -$108K – 1317
2016
Q1 		$108K Sell
10,270
-11,260
-52% -$124K ﹤0.01% 1196
2015
Q4 		$255K Buy
21,530
+10,930
+103% +$134K ﹤0.01% 1020
2015
Q3 		$124K Buy
+10,600
New +$140K ﹤0.01% 1054

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Balyasny Asset Management's LFCR Position: Q4 2025 in Review

Balyasny Asset Management sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 13,699 shares — an estimated $101K sold.

Balyasny Asset Management first reported a position in LFCR in Q3 2015 and held it in 9 quarters. The position peaked at $459K in Q4 2023. 103 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Balyasny Asset Management reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 13,699 Lifecore Biomedical shares in Q4 2025, an estimated $101K.
  • Balyasny Asset Management first reported a position in Lifecore Biomedical in Q3 2015 and held it in 9 quarters.
  • Balyasny Asset Management's Lifecore Biomedical position peaked at $459K in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.